Effectiveness and safety of mesenchymal stem/stromal cell for radiation-induced hyposalivation and xerostomia in previous head and neck cancer patients (MESRIX-III): a study protocol for a single-centre, double-blinded, randomised, placebo-controlled, phase II study
DiscussionThe trials will investigate the efficacy and safety of ASC injection to the submandibular gland as a potential new treatment for post-radiation xerostomia. We hope the results will pave the way for a clinically relevant treatment to ameliorate patients with xerostomia, a severely hampering condition.Trial registrationThe study is approved by the Danish Data Protection Agency (protocol number P-2020-1164), the National Ethics Committee protocol number: (Protocol number: 1802872), and the Danish Medical Agency (2018-000348-24). The protocol was registered at the ClinicalTrials.gov database (NCT04776538). (Source: Trials)
Source: Trials - September 1, 2023 Category: Research Source Type: clinical trials
Treatment of Post-radiation Xerostomia With Allogeneic Mesenchymal Stromal Stem Cells
Condition: Xerostomia Following Radiotherapy Intervention: Biological: allogeneic mesenchymal stromal stem cells Sponsors: Institute of Oncology Ljubljana; Blood Transfusion Centre of Slovenia; University Medical Centre Ljubljana; University of Ljubljana Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 25, 2023 Category: Research Source Type: clinical trials
